Summary of KING PHARMACEUTICALS INC

Item 2.01. Completion of Acquisition or Disposition of Assets.
On January 5, 2009, King Pharmaceuticals, Inc. ("King") filed a Current Report on Form 8-K to report the completion of its acquisition of all of the outstanding shares of Class A Common Stock, together with the associated preferred stock purchase rights, of Alpharma Inc. King is filing this amendment to the January 5 Current Report to include the financial information required by Item 9.01.

Table of Contents

Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
1. Alpharma's audited consolidated financial statements as of December 31, 2007 and 2006 and for each of the three years ended December 31, 2007, 2006, and 2005 are attached as Exhibit 99.1 and are incorporated herein by reference.

2. Alpharma's condensed consolidated financial statements as of September 30, 2008, and for the three and nine months ended September 30, 2008 and 2007, are attached as Exhibit 99.2 and are incorporated herein by reference.

(b) Pro Forma Financial Information. Unaudited pro forma condensed financial information for the twelve months ended December 31, 2007 and the nine months ended September 30, 2008, is attached as Exhibit 99.3 and is incorporated herein by reference.
(d) Exhibits.

Exhibit No.   Description

23.1          Consent of Independent Registered Public Accounting Firm.

99.1          Audited consolidated financial statements of Alpharma, Inc. as of
              December 31, 2007 and 2006 and for each of the three years ended
              December 31, 2007, 2006 and 2005.

99.2          Unaudited condensed consolidated financial statements of Alpharma, Inc.
              as of September 30, 2008, and for the three and nine months ended
              September 30, 2008 and 2007.

99.3          Unaudited pro forma financial information for the twelve months ended
              December 31, 2007 and for the nine months ended September 30, 2008.

Table of Contents